Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) is on recovery track with 328.57% gain from a 1-year low price of $0.07. The company lost -4.76% to attain the price of $0.3 on 02/20/2019. Throughout the recent session, the prices were hovering between $0.29 and $0.325. These shares are 566.67% off its target price of $2 and the current market capitalization stands at $74.4M. The recent change has given its price a 20.56% lead over SMA 50 and -86.73% deficit over its 52-week high. The stock witnessed 7.57% gains, -19.09% declines and -83.61% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found SGYP’s volatility during a week at 9.34% and during a month it has been found around 14.96%.Synergy Pharmaceuticals Inc. (SGYP) Top Holders
Institutional investors currently hold around $11 million or 20.7% in SGYP stock. Look at its top three institutional owners. Blackrock Inc. owns $3.81 million in Synergy Pharmaceuticals Inc., which represents roughly 5.12% of the company’s market cap and approximately 34.63% of the institutional ownership. Similar statistics are true for the second largest owner, State Street Corp, which owns 4,341,539 shares of the stock are valued at $1.37 million. The third largest holder is Vanguard Group Inc, which currently holds $998 thousand worth of this stock and that ownership represents nearly 1.34% of its market capitalization.Synergy Pharmaceuticals Inc. 13F Filings
At the end of December reporting period, 28 institutional holders increased their position in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) by some 4,991,345 shares, 94 decreased positions by 64,904,582 and 21 held positions by -33,702,553. That puts total institutional holdings at 36,193,374 shares, according to SEC filings. The stock grabbed 13 new institutional investments totaling 1,490,964 shares while 56 institutional investors sold out their entire positions totaling 18,159,847 shares.Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Insider Trades
Multiple company employees have indulged in significant insider trading. Synergy Pharmaceuticals Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that 10% Owner Paulson & Co. Inc. has sold 8,750,000 shares of Synergy Pharmaceuticals Inc. (SGYP) in trading session dated Nov. 10, 2017. These shares are worth $24,675,000 and were traded at $2.82 each. The SEC filing shows that Paulson & Co. Inc. performed a sale of 26,287 shares. The 10% Owner disposed these shares by way of transaction on Aug. 07, 2017. The company’s shares were given away at $3.77 per share worth to an income of some $99,102 on account of Paulson & Co. Inc..
CEO, Jacob Gary S, purchased 5,680 common shares of Synergy Pharmaceuticals Inc. (SGYP) in the open market. In a transaction dated May. 26, 2017, the shares were bought at an average price of $3.52, giving away a sum of $19,994. After this purchase, 402,679 common shares of SGYP are directly owned by the insider, with total stake valued at $120,804.
In the transaction dated May. 26, 2017, the great number of shares acquired came courtesy the Director; Brancaccio John P added a total of 6,500 shares at an average price of $3.59, amounting to approximately $23,335. The insider now directly owns 30,444 shares worth $9,133.Synergy Pharmaceuticals Inc. (SGYP) Analyst Guide
Several analysts have released their opinion on Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), with 0 analysts believing it is a strong buy. Whereas 2 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 3 average brokerage recommendation.